Why the study?
The risks of major adverse cardiac events and major bleeding across different antithrombotic regimens in Asian patients with AF undergoing stent insertions needed to be compared.
Does double or triple antithrombotic therapy improve MACEs or increase major bleeding compared to DAPT in Asian patients with nonvalvular AF undergoing PCI with stenting?
Cohort (n=10,208)
Yes
Does double or triple antithrombotic therapy improve MACEs or increase major bleeding compared to DAPT in Asian patients with nonvalvular AF undergoing PCI with stenting?
In Asian patients with AF undergoing PCI, double therapy provides comparable ischemic protection to triple therapy and DAPT, while avoiding the significantly increased major bleeding risk associated with triple therapy.
Answers are grounded in this paper and cite their sources.
Triple therapy may raise bleeding risk without lowering MACEs versus DAPT or double therapy in Asian AF patients post-stent; leaves open optimal regimen choice pending prospective trials.
This study aims to compare the risks of major adverse cardiac events (MACEs), including cardiovascular death, myocardial infarction, ischemic stroke and transient ischemic attack, and major bleeding across different antithrombotic regimens in Asian patients with atrial fibrillation (AF) with stent insertions. We conducted a retrospective cohort study using Taiwan's National Health Insurance Research Database and National Mortality Registry. A total of 10,208 patients with nonvalvular AF who had undergone percutaneous coronary intervention with stents for the first time in 2007-2017 were identified. Most patients (68.4%) were prescribed dual antiplatelet therapy (DAPT) at discharge. During follow-up, the use of anticoagulants increased, and double therapy (an antiplatelet plus an anticoagulant) was the most frequently prescribed therapy. The risks of MACEs were comparable in double therapy and had a similar risk of MACEs compared with DAPT (adjusted hazard ratio (aHR) 0.86, 95% confidence interval (CI) 0.67-1.11). Triple therapy (DAPT plus an anticoagulant) also had similar effectiveness to double therapy (aHR 1.23, 95% CI 0.84-1.80) or DAPT (aHR 1.06, 95% CI 0.77-1.45). However, triple therapy was associated with a nearly twofold higher major bleeding risk than DAPT and double therapy (aHR 1.97, 95% CI 1.31-2.94 and aHR 1.80, 95% CI 1.10-2.95, respectively). DAPT was the most frequently prescribed antithrombotic regimen at discharge for Asian patients with AF who had undergone stent insertions. DAPT and double and triple therapy had comparable effectiveness, but triple therapy had a significantly higher major bleeding risk than either DAPT or double therapy.
No takes yet. Share an insight, caveat, or question.
Chueh et al. (2022) conducted a cohort in nonvalvular atrial fibrillation with stent insertions (n=10,208). Double therapy (antiplatelet plus anticoagulant) vs. Dual antiplatelet therapy (DAPT) was evaluated on major adverse cardiac events (MACEs), including cardiovascular death, myocardial infarction, ischemic stroke and transient ischemic attack (aHR 0.86, 95% CI 0.67-1.11).
Synapse has enriched 10 related papers. Consider them for comparative context: